Novo Nordisk's first phase III data for weekly insulin to be released in few months

The first data from Novo Nordisk’s phase III program, which goes under the name Onwards, with once-weekly insulin Icodec will arrive within a few months, says Novo exec Martin Holst Lange at the company’s capital markets day.
Photo: Novo Nordisk Pharmatech/PR
Photo: Novo Nordisk Pharmatech/PR
by marketwire, translated by daniel pedersen

Novo Nordisk is expecting to conclude its phase III program, dubbed Onwards, with its once-weekly insulin Icodec in 2022.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
  • Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
    Must contain at least 2 characters
    Must contain at least 2 characters

    Get full access for you and your coworkers

    Start a free company trial today

    Share article

    Sign up for our newsletter

    Stay ahead of development by receiving our newsletter on the latest sector knowledge.

    Newsletter terms

    Front page now

    Foto: Mike Blake/Reuters/Ritzau Scanpix

    Gilead Sciences CMO to leave early 2025

    For subscribers

    Further reading